Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

Exclusion Criteria

• •Uncontrolled Central Nervous System (CNS) metastasis.
• •Previous exposure to monoclonal antibodies, signal transduction inhibitors or Epidermal growth factor receptor (EGFR) targeting therapy
• •Concurrent malignancy
• •Prior chemotherapy for NSCLC
• •Pre-existing ascites grade ≥ 2 or pericardial effusion grade ≥ 2
• •Superior vena cava syndrome contra-indicating hydration
• •White Blood Cells (WBC) \< 3,000/mm³
• •Absolute neutrophile count (ANC) \< 1,500/mm³
• •Platelet \< 100,000/mm³
• •Hemoglobin (Hgb) \< 9.0 g/dL
• •Total bilirubin \> 1.5 x Upper limit of normal (ULN).
• •Aspartate aminotransferase (AST) or Alanine-aminotransferase (ALT) \> 5.0 x ULN.
• •Serum creatinine \>1.25 x ULN and calculated creatinine clearance \<60mL/min